Considering its the potential effects on immune evasion, YTHDF1 siRNA is packaged in engineered small extracellular vesicles (sEVs) for GC treatment, producing anti-cancer efficiency by achieving self-presentation of the immunogenic tumor cells to stimulate robust cytotoxic T lymphocytes responses [135]. This evidence concerns the gene YTHDF1 and neoplasm.